Colón-López Vivian, Del Toro-Mejías Lizbeth M, Ortiz Ana P, Tortolero-Luna Guillermo, Palefsky Joel M
Department of Health Services Administration, Graduate School of Public Health, University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico.
P R Health Sci J. 2012 Dec;31(4):227-31.
An HPV vaccine has been approved for men aged 9 to 26 in the US for the prevention of genital warts and anal cancer. The purpose of this study is to describe 1) HPV vaccine awareness, 2) willingness to get the HPV vaccine and 3) perceived susceptibility to HPV-related cancers and genital warts among men 18-26 years old who attend an STI clinic in San Juan, Puerto Rico (PR).
A cross-sectional pilot study consisting of 206 HIV+/HIV- men. For purpose of this analysis, only those participants aged <or=26 years old were included in this analysis (n=46).
None of the study participants had been vaccinated against HPV. Fewer than a third knew about the HPV vaccine (28.3%). However, more than half (76.9%) were willing to be vaccinated against HPV. Information sources about the HPV vaccine included their female sexual partners (13.0%), a female sexual partner who received the vaccine (8.7%) and a male sexual partner (2.2%). Most participants'reported that the main reason that would increase their willingness to get vaccinated was if a physician recommend the vaccine (95.7%). Perceived susceptibility was low, particularly for anal and oral cancer.
This pilot study shows poor awareness of the HPV vaccine, although willingness to getting the HPV vaccine was high among those who knew about the vaccine. Future studies should try to evaluate this paradox and study in depth willingness and barriers to vaccination among male sub-groups, such as men who have sex with men (MSM). These studies should also evaluate predictors of uptake of the HPV vaccine among men in this and other STI clinics in PR, in order to develop interventions to increase male vaccination.
在美国，一种人乳头瘤病毒（HPV）疫苗已被批准用于9至26岁的男性，以预防尖锐湿疣和肛门癌。本研究的目的是描述：1）HPV疫苗知晓率；2）接种HPV疫苗的意愿；3）在波多黎各圣胡安一家性传播感染（STI）诊所就诊的18至26岁男性中，对HPV相关癌症和尖锐湿疣的感知易感性。
一项横断面试点研究，共有206名HIV阳性/阴性男性参与。出于本分析目的，仅纳入年龄≤26岁的参与者（n = 46）。
研究参与者中无人接种过HPV疫苗。知晓HPV疫苗的人不到三分之一（28.3%）。然而，超过一半（76.9%）的人愿意接种HPV疫苗。HPV疫苗的信息来源包括他们的女性性伴侣（13.0%）、接种过该疫苗的女性性伴侣（8.7%）和男性性伴侣（2.2%）。大多数参与者表示，如果医生推荐接种疫苗，这将是增加他们接种意愿的主要原因（95.7%）。感知易感性较低，尤其是对于肛门癌和口腔癌。
这项试点研究表明，HPV疫苗知晓率较低，尽管在知晓该疫苗的人群中接种意愿较高。未来的研究应尝试评估这一矛盾现象，并深入研究男性亚组（如同性恋男性）接种疫苗的意愿和障碍。这些研究还应评估在波多黎各这家及其他STI诊所中男性接种HPV疫苗的预测因素，以便制定干预措施来提高男性接种率。
